CEL-SCI Corporation (NYSEAMEX:CVM)’s investigation on Multikine

Boston, MA 04/05/2013 (wallstreetpr) – CEL-SCI Corporation (NYSEAMEX:CVM) is a global leader in the research and development of cancer treatment and drugs, by utilizing the immune system of the body. The company is presently involved in a pioneering investigation therapy called Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. Additionally, the company is involved in several immunological projects. The latest stress is on the immunization as a possible treatment for H1N1 hospitalized patients- a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its groundbreaking LEAPS technology platform.

The aggregate market value of the voting stock held by non-affiliates of the CVM is based on the closing sales price of the common stocks on March 31, 2012, which was $120,199,660. Currently trading at $0.278, up by 0.51%. Yesterday, its stock value reached as high as $0.28 and dipped at $0.2426. Considering the quoted rates of the previous day, the market share price gained 10.26% yesterday, with a significant volume rise in the trading. A study of last three months trading revealed that on an average around 1.2 million shares of CEL-CSI were traded on NASDAQ. A further study of the year long trading reveals, that the value of the stocks reached an all time high of $0.58 and the lowest quoted rate was $0.205. With a market capitalization of around $85 million, the company has made a singular presence of trading on the stock exchange.

With revolutionizing technology in new age immunological studies, with a view to resolve the long craving demands of Medical Science, CEL-SCI is all set to draw its own horizon in the global markets. Its current presence on the NASDAQ is a robust indication of its ambitions and organizational growth. The principal traders of the NASDAQ have shown a considerable interest in this company. Subsequently, investing in CVM stocks will be a brilliant choice for investors who have a vision of the future. The rest is for the investors to find out in the coming times.

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. While reading this article one must assume that we may be compensated for posting this content on our website.

Published by Donna Fago

I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.

Recent Stories

SignUp Now For Our Featured Newsletter